Abstract
We investigated the in vitro and in vivo antimicrobial potential of a selective serotonin reuptake inhibitor sertraline hydrochloride, against clinical isolates of bacteria and Candida species. Minimum Inhibitory Concentration of sertraline against 161 human isolates of 12 Gram negative and 5 Gram positive genera, Candida albicans ATCC10231 and Candida tropicalis ATCC13803 was determined by spot inoculation, broth and agar dilution methods along with its postantibiotic effect following a short drug exposure. The toxicity and protective efficacy was tested in vivo with a mousevirulent strain of Salmonella typhimurium NCTC74.The MIC was 20-200μg/ml for bacteria, and 200μg/ml for Candida. The growth inhibitory study with Bacillus subtilis UC564 and Shigella dysenteriae NCTC599/52 revealed that the drug is bacteriostatic at its MIC and cidal at higher concentrations. Study on its post-antibiotic effect following a short drug exposure revealed that Sertraline has a time- and dose-dependent effect. Treatment for 4h at concentrations below and equipotent to the minimal static concentration resulted in a lag of regrowth at 8-24h for Candida isolates. The in vivo study with Salmonella typhimurium in Swiss mice showed that the median lethal dose was 1.9 x 107 cfu and 50 LD50 was 0.95x109. Interestingly, the drug at a non-toxic single dose provides significant protection (P<0.001) to the mice challenged with S. typhimurium. Sertraline remarkably reduced the number of viable bacteria in organ homogenates and blood of the treated animals and demonstrate both in vitro and in vivo antibacterial potential at lower dose than its predesignated pharmacological activity.
Keywords: Sertraline hydrochloride, SSRI, antibacterial activity, antifungal activity, non-antibiotic
Anti-Infective Agents
Title:Evaluation of In Vivo and In Vitro Antimicrobial Activities of a Selective Serotonin Reuptake Inhibitor Sertraline Hydrochloride
Volume: 10 Issue: 2
Author(s): Amalesh Samanta, Debprasad Chattopadhyay, Chandrima Sinha, Ananda Dulal Jana, Soma Ghosh, Anurup Mandal, Ananya Banerjee, Oliver Hendricks, Jorn B. Christensen and Jette Elisabeth Kristiansen
Affiliation:
Keywords: Sertraline hydrochloride, SSRI, antibacterial activity, antifungal activity, non-antibiotic
Abstract: We investigated the in vitro and in vivo antimicrobial potential of a selective serotonin reuptake inhibitor sertraline hydrochloride, against clinical isolates of bacteria and Candida species. Minimum Inhibitory Concentration of sertraline against 161 human isolates of 12 Gram negative and 5 Gram positive genera, Candida albicans ATCC10231 and Candida tropicalis ATCC13803 was determined by spot inoculation, broth and agar dilution methods along with its postantibiotic effect following a short drug exposure. The toxicity and protective efficacy was tested in vivo with a mousevirulent strain of Salmonella typhimurium NCTC74.The MIC was 20-200μg/ml for bacteria, and 200μg/ml for Candida. The growth inhibitory study with Bacillus subtilis UC564 and Shigella dysenteriae NCTC599/52 revealed that the drug is bacteriostatic at its MIC and cidal at higher concentrations. Study on its post-antibiotic effect following a short drug exposure revealed that Sertraline has a time- and dose-dependent effect. Treatment for 4h at concentrations below and equipotent to the minimal static concentration resulted in a lag of regrowth at 8-24h for Candida isolates. The in vivo study with Salmonella typhimurium in Swiss mice showed that the median lethal dose was 1.9 x 107 cfu and 50 LD50 was 0.95x109. Interestingly, the drug at a non-toxic single dose provides significant protection (P<0.001) to the mice challenged with S. typhimurium. Sertraline remarkably reduced the number of viable bacteria in organ homogenates and blood of the treated animals and demonstrate both in vitro and in vivo antibacterial potential at lower dose than its predesignated pharmacological activity.
Export Options
About this article
Cite this article as:
Samanta Amalesh, Chattopadhyay Debprasad, Sinha Chandrima, Dulal Jana Ananda, Ghosh Soma, Mandal Anurup, Banerjee Ananya, Hendricks Oliver, B. Christensen Jorn and Elisabeth Kristiansen Jette, Evaluation of In Vivo and In Vitro Antimicrobial Activities of a Selective Serotonin Reuptake Inhibitor Sertraline Hydrochloride, Anti-Infective Agents 2012; 10 (2) . https://dx.doi.org/10.2174/2211362611208020095
DOI https://dx.doi.org/10.2174/2211362611208020095 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
Call for Papers in Thematic Issues
An Overview of Drugs for Multiple Targets and Variants of SARS-CoV-2 Through Artificial Intelligence, Machine Learning, Deep Learning, and Experimental Analysis
The emergence and rapid evolution of SARS-CoV-2 variants have posed significant challenges in the ongoing fight against the COVID-19 pandemic. The development of effective treatments for multiple viral targets and variants demands innovative approaches, including artificial intelligence (AI), machine learning (ML), and deep learning (DL) techniques. This special issue aims ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: In Silico Studies in Drug Research Against Neurodegenerative Diseases
Current Neuropharmacology Human Cognitive and Neuro-Psychiatric Bio-Markers in the Cardiac Peri-Operative Patient
Current Molecular Medicine Patent Selections
Recent Patents on Drug Delivery & Formulation Neurophysiology of Sleep and Wakefulness: Basic Science and Clinical Implications
Current Neuropharmacology The Concept of “Neuroprotection” in Neurological Diseases
Current Neuropharmacology Catastrophic Antiphospholipid Syndrome - 20 Years Later
Current Rheumatology Reviews Is there any Additional Prognostic Value of Central Blood Pressure Wave Forms Beyond Peripheral Blood Pressure?
Current Pharmaceutical Design Erythropoietin: A Neuroprotective Agent in Cerebral Hypoxia, Neurodegeneration, and Epilepsy
Current Pharmaceutical Design Aging and DNA Methylation
Current Chemical Biology Leptin Induces Neuroprotection Neurogenesis and Angiogenesis after Stroke
Current Neurovascular Research Editorial [Hot Topic: Anti-Amyloidogenic/Protein-Misfolding Therapies in Amyloidosis and Other Protein-Misfolding Disorders (Executive Editor: Masahito Yamada)]
Current Pharmaceutical Design Possible Involvement of Muscarinic Receptors in Psychiatric Disorders: A Focus on Schizophrenia and Mood Disorders
Current Molecular Medicine Covid-19 Susceptibility and Severity Might be Modified by Vitamin D Status: Theoretical and Practical Considerations
Current Respiratory Medicine Reviews Click Chemistry, A Potent Tool in Medicinal Sciences
Current Medicinal Chemistry Cholesterol and Apoe: A Target for Alzheimers Disease Therapeutics
Current Drug Targets - CNS & Neurological Disorders Cell-and Gene-based Therapeutic Approaches for Neurological Deficits in Mucopolysaccharidoses
Current Pharmaceutical Biotechnology Comparison of Serum Choline and Trimethylamine N-oxide after Ingestion of Alpha Glyceryl Phosphoryl Choline and Choline Salts
Current Nutraceuticals <i>Thespesia populnea</i>: An Ethnomedicinal, Phytochemical and Pharmacological Review
The Natural Products Journal Synthesis of Chiral 2-(6,8-dichloro-4-methyl-1,1,3-trioxo-3,4-dihydro-1H-1λ6-benzo[1,2,4]thiadiazin-2-yl) Carboxylic Acids Derived from Enantiomeric Amino Acids
Letters in Organic Chemistry Serum Cytokine Profile in Alzheimer's Disease Patients After Ingestion of an Antioxidant Beverage
CNS & Neurological Disorders - Drug Targets